RECURRENT OSTEOSARCOMA
Clinical trials for RECURRENT OSTEOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OSTEOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT OSTEOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on hard-to-treat bone cancer in early trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called FH-FOLR1 ST CAR T cells for people with advanced osteosarcoma (a type of bone cancer) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a …
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
New drug combo aims to control tough bone cancer in teens and young adults
Disease control Recruiting nowThis study tests whether combining two drugs, atezolizumab and cabozantinib, can help control osteosarcoma that has come back or spread. It is for adolescents and young adults aged 12 and older whose cancer did not respond to standard treatments. The goal is to slow cancer growth…
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with Hard-to-Treat cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …
Matched conditions: RECURRENT OSTEOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 06, 2026 16:01 UTC